Pfizer completes the trials of its vaccine with 95% efficacy and will request an authorization from the US "in days"

• Direct. Last minute on the coronavirus

• Health: When will Moderna and Pfizer vaccines arrive in Spain

• Q & A. Doubts and certainties about Moderna's vaccine

After just over a week ago, the pharmaceutical company Pfizer announced that its vaccine against

was 90% effective in an initial analysis of the phase 3 trial, this Wednesday it has assured, after finishing the tests, that the final results show that it prevents infection in 95% of cases and does

.

In addition, the company has highlighted that the vaccine is 94% safe among those over 65 years of age, who are more vulnerable to the virus and who may not respond well to some types of vaccine.

The pharmaceutical company, which has developed the vaccine together with its German partner BioNTech, has added that, following the success of the clinical trials, it plans to apply to the US Food and Drug Administration (FDA) for

.

This means that if the FDA approves Pfizer's request, the company could have

and up to 1.3 billion by the end of 2021.

In the race to obtain a vaccine to end the pandemic that has changed our lives, the new results from Pfizer and BioNTech are published just days after Modern Pharmaceutical company announced on Monday that its vaccine, one of the most advanced and closer to the goal, it was almost 95% effective.

Albert Bourla, CEO of Pfizer, said in a statement that "The results of the study mark an important step in this historic eight-month journey to present a vaccine capable of helping to end this devastating pandemic. With hundreds of thousands of people around the world infected every day, we urgently need to bring a safe and effective vaccine to the world. "

In this statement, the company has detailed that the effectiveness was kept constant according to criteria such as age, gender or race.

In this latest trial, which will continue to collect data for two more years, 43,661 volunteers participated.

About 42% of them had diverse racial and ethnic backgrounds, and

.

"Our goal from the beginning was to design and develop a vaccine that would generate rapid and powerful protection against Covid-19 with a benign tolerance profile at all ages. We believe that we have achieved this with our candidate BNT162b2 vaccine in all groups of age studied so far and we hope to share more details with the regulatory authorities, "said Ugur Sahin, co-founder of BioNTech.

Of the 170 infected, 162 were from the placebo group

The analysis of the data obtained indicates that of the 170 patients who were infected with coronavirus, 162 corresponded to the placebo group, compared to the eight cases that did receive the two-dose vaccine.

Also,

.

Therefore, these data mean that the vaccine not only prevents mild cases, but also those more serious cases of the disease that require hospitalization or that can even lead to death.

Regarding the effects of the vaccine considered serious, Pfizer has reported that

has only occurred

, a percentage that increased to 3.7% after the second dose;

and headache also in 2%.

On the other hand, according to the company, older adults tended to suffer fewer symptoms after vaccination, or milder if they occurred, than younger people.

According to the criteria of The Trust Project

Know more

• Coronavirus

• Covid 19

• Vaccinations

Immunization Trip to the Chinese city where they put the coronavirus vaccine for 50 euros

Immunization Moderna's vaccine begins the process for its authorization in Europe

When will Moderna and Pfizer vaccines arrive in Spain?

See links of interest

• News

• Translator

• Programming

• Films

• Topics

• 2021 business calendar

• Coronavirus

• Asunta

• TD Systems Baskonia - Fenerbahce Istanbul

• Spain - Germany, live

• Valencia Basket - Panathinaikos